Dapaglifozin use in pediatric IgA nephropathy: a single-center real-life experience

Immunoglobulin A nephropathy (IgAN) represents the leading cause of primary glomerulonephritis worldwide and exhibits a heterogeneous presentation, including microscopic or macroscopic hematuria, variable degrees of proteinuria, and the potential for long-term renal decline [1].While renin-angiotensin system (RAS) inhibition forms the basis of current supportive management, a substantial subset of pediatric patients continue to experience persistent proteinuria despite maximized therapy [2].In recent years, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as promising renoprotective agents in adults with chronic kidney disease, including IgAN [3,4].